MTOR and cancer: Based on structure and/or known drug target, the compounds fall into one of four groupings: those containing a methoxybenzaldehyde moiety (aniracteam and avobenzone); anti-cancer agents (cladribine, gemcitabine, floxuridine, clofarabine, bleomycin and docetaxel), mTOR inhibitors (temsirolimus and rapamycin) and topoisomerase II inhibitors (mitoxantrone and teniposide).